The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...

This recognition reflects the robust clinical evidence supporting NeuroAiDtmII, as well as the uniqueness of its formulation, ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Taking a break from resistance training doesn’t ...

ZYUS Life Sciences Corporation (the "Company") , a clinical?stage life sciences company focused on the development and commercialization of novel non?opioid drug candidates for pain management, is ...